FY 2006 appropriation for effectiveness research
House/Labor, HHS & Education Subcommittee mark for fiscal 2006 appropriations budgets $15 mil. for AHRQ to perform comparative effectiveness research. AHRQ received $15 mil. for the program in FY 2005 (1"The Pink Sheet" Sept. 20, 2004, p. 14)...
You may also be interested in...
Funding for prescription drug comparative effectiveness research is included in the HHS fiscal year 2005 appropriations bill reported to the full Senate Sept. 15
The decision limits US FDA discretion in determining how to regulate products that seem to meet both drug and device standards.
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.